Pharmacokinetic Data of Dolutegravir in Second-line Treatment of Children With Human Immunodeficiency Virus: Results From the CHAPAS4 Trial

BACKGROUND: Dolutegravir (DTG), combined with a backbone of 2 nucleoside reverse transcriptase inhibitors, is currently the preferred first-line treatment for human immunodeficiency virus (HIV) in childhood. CHAPAS4 is an ongoing randomized controlled trial investigating second-line treatment option...

Descripción completa

Detalles Bibliográficos
Autores principales: Bevers, Lisanne A H, Waalewijn, Hylke, Szubert, Alexander J, Chabala, Chishala, Bwakura-Dangarembizi, Mutsa, Makumbi, Shafic, Nangiya, Joan, Mumbiro, Vivian, Mulenga, Veronica, Musiime, Victor, Burger, David M, Gibb, Diana M, Colbers, Angela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Major Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10640690/
https://www.ncbi.nlm.nih.gov/pubmed/37280040
http://dx.doi.org/10.1093/cid/ciad346

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10640690/
https://www.ncbi.nlm.nih.gov/pubmed/37280040
http://dx.doi.org/10.1093/cid/ciad346

Ejemplares similares